Antiphospholipid antibodies: pinning risk on a moving target.
Kathryn
K
Kirchoff-Torres
Steven R
SR
Levine
D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000276:immunology*; D002545:Brain Ischemia / Q000150:complications / Q000453:epidemiology; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood / Q000276:immunology; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000276:immunology*; D012306:Risk; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D020521:Stroke / Q000453:epidemiology* / Q000276:immunology*; D013927:Thrombosis / Q000097:blood / Q000276:immunology*; D055815:Young Adult; D053482:beta 2-Glycoprotein I / Q000502:physiology
D017152:Antibodies, Antiphospholipid; D003278:Contraceptives, Oral, Hormonal; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I